FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies
Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…
CertaraAugust 26, 2024
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator
The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…
CertaraAugust 26, 2024
Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…
CertaraAugust 26, 2024
The Uncertain Path Forward for Psychedelic Medicine
Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…
CertaraAugust 26, 2024
Streamline your clinical trials with automated metadata management
When it comes to efficient clinical study build, content is king. Most importantly: metadata content.…
CertaraAugust 26, 2024
Regulatory requirements for annotated CRFs made easy
aCRFs are a mandatory requirement of the FDA, and therefore a key submission deliverable for…
CertaraAugust 26, 2024
Resmetirom: A pioneering NASH clinical program
Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…
CertaraAugust 23, 2024
Overcoming CMC Challenges in Cell and Gene Therapy: Part I
In this Manufacturing Chemist article, Certara's Drs. Hien Anh Bruno and Deven Shah discuss the…
CertaraAugust 23, 2024
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa. — August 21, 2024 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraAugust 21, 2024
